Celecoxib alleviates nociceptor sensitization mediated by interleukin-1beta-primed annulus fibrosus cells
European Spine Journal · 2023
DOI: 10.1007/s00586-023-07672-x ↗Kurz gefasst
Fachartikel in der Zeitschrift European Spine Journal, 2023. Verfasst von Junxuan Ma und 14 weiteren Autor:innen. Beteiligte Einrichtung: AO Research Institute Davos, Clavadelerstrasse 8, 7270, Davos, Switzerland. Hauptthemen laut MEDLINE: Annulus Fibrosus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss orthopaedics, AO Foundation, AO Spine.
Abstract (Originalsprache)
Purpose
This study aims to analyze the effect of pro-inflammatory cytokine-stimulated human annulus fibrosus cells (hAFCs) on the sensitization of dorsal root ganglion (DRG) cells. We further hypothesized that celecoxib (cxb) could inhibit hAFCs-induced DRG sensitization. Methods hAFCs from spinal trauma patients were stimulated with TNF-α or IL-1β. Cxb was added on day 2. On day 4, the expression of pro-inflammatory and neurotrophic genes was evaluated using RT-qPCR. Levels of prostaglandin E2 (PGE-2), IL-8, and IL-6 were measured in the conditioned medium (CM) using ELISA. hAFCs CM was then applied to stimulate the DRG cell line (ND7/23) for 6 days. Then, calcium imaging (Fluo4) was performed to evaluate DRG cell sensitization. Both spontaneous and bradykinin-stimulated (0.5 μM) calcium responses were analyzed. The effects on primary bovine DRG cell culture were performed in parallel to the DRG cell line model.
Results
IL-1ß stimulation significantly enhanced the release of PGE-2 in hAFCs CM, while this increase was completely suppressed by 10 µM cxb. hAFCs revealed elevated IL-6 and IL-8 release following TNF-α and IL-1β treatment, though cxb did not alter this. The effect of hAFCs CM on DRG cell sensitization was influenced by adding cxb to hAFCs; both the DRG cell line and primary bovine DRG nociceptors showed a lower sensitivity to bradykinin stimulation.
Conclusion
Cxb can inhibit PGE-2 production in hAFCs in an IL-1β-induced pro-inflammatory in vitro environment. The cxb applied to the hAFCs also reduces the sensitization of DRG nociceptors that are stimulated by the hAFCs CM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AO Research Institute Davos, Clavadelerstrasse 8, 7270, Davos, Switzerland.
- ETH Zurich, Zurich, Switzerland.
- École des Mines de Saint-Étienne, Saint-Etienne, France.
- Department of Orthopaedic Surgery and Traumatology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, 3010, Bern, Switzerland.
- Spine Surgery, Sonnenhof Spital, Buchserstrasse 30, 3006, Bern, Switzerland.
- Department of Orthopedics and Trauma Surgery, Faculty of Medicine, Medical Center-Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
Förderung
- Swiss orthopaedics
- AO Foundation
- AO Spine
- University of Bern
Zitieren
APA
Ma, J., Häne, S., Eglauf, J., Pfannkuche, J., Soubrier, A., Li, Z., Peroglio, M., Hoppe, S., Benneker, L., Lang, G., Wangler, S., Alini, M., Creemers, L. B., Grad, S., & Häckel, S. (2023). Celecoxib alleviates nociceptor sensitization mediated by interleukin-1beta-primed annulus fibrosus cells. European Spine Journal. https://doi.org/10.1007/s00586-023-07672-x
Vancouver
Ma J, Häne S, Eglauf J, Pfannkuche J, Soubrier A, Li Z, et al. Celecoxib alleviates nociceptor sensitization mediated by interleukin-1beta-primed annulus fibrosus cells. European Spine Journal. 2023. doi:10.1007/s00586-023-07672-x
BibTeX
@article{Ma2023,
author = {Ma, Junxuan and Häne, Surya and Eglauf, Janick and Pfannkuche, Judith and Soubrier, Astrid and Li, Zhen and Peroglio, Marianna and Hoppe, Sven and Benneker, Lorin and Lang, Gernot and Wangler, Sebastian and Alini, Mauro and Creemers, Laura B and Grad, Sibylle and Häckel, Sonja},
title = {Celecoxib alleviates nociceptor sensitization mediated by interleukin-1beta-primed annulus fibrosus cells},
journal = {European Spine Journal},
year = {2023},
doi = {10.1007/s00586-023-07672-x}
}
EUVIMED